Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of macitentan in Eisenmenger syndrome (AC-055-305 extension)
2012-004411-31Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in Eisenmenger syndrome, sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term safety of macitentan, Long-term tolerability of macitentan and 1 more. Started Jan 2013; status: completed.
02
Drugs
macitentan
03
Conditions
Eisenmenger syndrome
Beyond the preview
Go deeper on 2012-004411-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004411-31.